secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-07-22T20:01:17+00:00
Accession:  0001664710-26-000038
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics CFO Keith Regnante resigns; Annita Tanini named interim CFO
------------------------------------------------------------------------------

- CFO Keith Regnante resigns effective Aug 3, 2026, voluntarily with no disagreement over accounting or controls.
- Annita Tanini, Corporate Controller and VP Finance, appointed interim principal financial and accounting officer effective Aug 4, 2026.
- Tanini receives $302,300 base salary, 30% target bonus, and severance of 6 months base plus COBRA.
- Regnante receives only accrued salary and expenses; no additional severance.
- Company has commenced search for a permanent CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000038/0001664710-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000038/kros-20260717.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer